【摘要】 近年来,随着一些新的化疗药物的出现,儿童白血病的治疗效果逐渐显著,患者的完全缓解率可达50%～80%。尽管如此,由白血病中的微小残留病(MRD)引起的复发仍然面临巨大的考验,并且体内残留的白血病细胞是白血病复发的根本原因。回顾性和前瞻性分析均已证实ALL和AML患者的MRD水平与治疗效果相关并能预测复发风险。目前MRD的检测技术已非常完善,可覆盖98%以上的ALL和大部分AML。如今,检测MRD的两种主要技术是流式细胞术(FCM)和聚合酶链式反应(PCR)。这两种技术在预测疾病复发和评估预后方面具有重要作用,并为儿童白血病的临床干预治疗提供了基础。更多还原

【Abstract】 In recent years,with the advent of new chemotherapy drugs,Treatment of childhood leukemia are increasingly visible,The patient’s complete remission rate is50% to80%.Nevertheless,Minimal residual disease(MRD)lead to relapse is still facing great challenges,Residual leukemia cells in the body are the roots of leukemia relapse.Both retrospective and prospective analyses have demonstrated that MRD levels in ALL and AML patients are associated with treatment outcomes and predict the risk of recurrence.At present,the detection technology of MRD is very perfect.It can cover more than98%of ALL and most AML.Today,the two main techniques for detecting MRD are flow cytometry(FCM)and polymerase chain reaction(PCR).Both of these techniques have an important role in predicting disease recurrence and assessing prognosis,and provide a basis for clinical intervention and treatment of childhood leukemia.更多还原